Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure
Prasad R. Konkalmatt, … , Pedro A. Jose, Ines Armando
Prasad R. Konkalmatt, … , Pedro A. Jose, Ines Armando
Published June 2, 2016
Citation Information: JCI Insight. 2016;1(8):e85888. https://doi.org/10.1172/jci.insight.85888.
View: Text | PDF
Research Article Inflammation Nephrology

Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure

  • Text
  • PDF
Abstract

Dopamine D2 receptor (DRD2) deficiency increases renal inflammation and blood pressure in mice. We show here that long-term renal-selective silencing of Drd2 using siRNA increases renal expression of proinflammatory and profibrotic factors and blood pressure in mice. To determine the effects of renal-selective rescue of Drd2 expression in mice, the renal expression of DRD2 was first silenced using siRNA and 14 days later rescued by retrograde renal infusion of adeno-associated virus (AAV) vector with DRD2. Renal Drd2 siRNA treatment decreased the renal expression of DRD2 protein by 55%, and DRD2 AAV treatment increased the renal expression of DRD2 protein by 7.5- to 10-fold. Renal-selective DRD2 rescue reduced the expression of proinflammatory factors and kidney injury, preserved renal function, and normalized systolic and diastolic blood pressure. These results demonstrate that the deleterious effects of renal-selective Drd2 silencing on renal function and blood pressure were rescued by renal-selective overexpression of DRD2. Moreover, the deleterious effects of 45-minute bilateral ischemia/reperfusion on renal function and blood pressure in mice were ameliorated by a renal-selective increase in DRD2 expression by the retrograde ureteral infusion of DRD2 AAV immediately after the induction of ischemia/reperfusion injury. Thus, 14 days after ischemia/reperfusion injury, the renal expression of profibrotic factors, serum creatinine, and blood pressure were lower in mice infused with DRD2 AAV than in those infused with control AAV. These results indicate an important role of renal DRD2 in limiting renal injury and preserving normal renal function and blood pressure.

Authors

Prasad R. Konkalmatt, Laureano D. Asico, Yanrong Zhang, Yu Yang, Cinthia Drachenberg, Xiaoxu Zheng, Fei Han, Pedro A. Jose, Ines Armando

×

Figure 3

Renal Drd2 silencing increases the expression of proinflammatory factors and blood pressure.

Options: View larger image (or click on image) Download as PowerPoint
Renal Drd2 silencing increases the expression of proinflammatory factors...
Mice were treated with nonsilencing siRNA (NSsiRNA) or dopamine receptor D2 (Drd2) siRNA by right renal subcapsular infusion via osmotic minipump for 28 days. (A) Renal cortical mRNA expression of TNF-α, monocyte chemoattractant protein 1 (MCP1), IL-6, fibronectin 1 (FN1), and collagen type 1a1 (Col1a1) was quantified by qRT-PCR. GAPDH mRNA was used for normalization of the data. n = 5–6/group, *P < 0.05 vs. NSsiRNA, Student’s t test. (B) Renal cortical protein expression of DRD2 (55 kDa), TNF-α (25 kDa), MCP1 (17 kDa), and IL-6 (25 kDa) was determined by immunoblot. One set of immunoblots is shown. Relative abundance of the proteins was normalized to GAPDH and expressed as a percentage of the NSsiRNA-treated group. n = 3–6/group, *P < 0.05 vs. NSsiRNA, Student’s t test. (C) Systolic blood pressures measured under pentobarbital anesthesia in mice before (Pre) and 28 days after (Post) siRNA infusion. n = 5–6/group, *P < 0.05 vs. all others, 1-way ANOVA and Tukey test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts